Concepedia

Publication | Closed Access

PIPAC-OX: A Phase I Study of Oxaliplatin-Based Pressurized Intraperitoneal Aerosol Chemotherapy in Patients with Peritoneal Metastases

DOI

56

Citations

23

References

2020

Year

Guowei Kim, Hon Lyn Tan, Raghav Sundar, Bettina Lieske, Cheng Ean Chee, Jingshan Ho, Asim Shabbir, Maria V. Babak, Wee Han Ang, Boon Cher Goh,
Clinical Cancer Research

Abstract

The recommended phase II dose is 120 mg/m<sup>2</sup>. Future studies should further delineate the efficacy and role of PIPAC oxaliplatin for peritoneal metastases.<i>See related commentary by de Jong et al., p. 1830</i>.

References

YearCitations

Page 1